In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.10.014
Abstract: OBJECTIVES The LUX-Lung 8 randomized trial (LL8) demonstrated a prolonged progression-free survival (PFS) in patients with metastatic squamous cell carcinoma (SCC) of the lung after treatment with afatinib compared with erlotinib. A secondary analysis of… read more here.
Keywords: her2 mutations; her4 mutations; lung; her2 her4 ... See more keywords